The benefit of cabozantinib treatment reported by the COSMIC 021 and PAPMET trials in pRCC patients led investigators to examine the efficacy of this drug in tRCC patients, especially because tRCC is similar to pRCC as it harbors high expression of c-MET, and TFE3 fusion proteins have been shown to bind to the MET promoter (82). Here, MET is linked to renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.